In addition to hematological tumors (Kawabata et al., 2021), elevated BCL6 protein levels have been observed in various solid tumors such as bladder carcinoma, breast cancer, and ovarian cancer (Fernando et al., 2019; Cardenas et al., 2017; De Santis et al., 2022). This evidence concerns the gene BCL6 and ovarian cancer.